Rebecca Myerson
Credentials: Associate Professor, Population Health Sciences
Email: rmyerson@wisc.edu
Address:
773 WARF Office Building
610 Walnut Street
Madison, WI 53726
- Home page
- Department of Population Health Sciences
- Additional information
- Curriculum Vitae
Rebecca Myerson is an Associate Professor in the Department of Population Health Sciences at the University of Wisconsin’s School of Medicine and Public Health. Her work measures the effects of health insurance policy on health care outcomes, and tests how the provision of information and assistance influences equitable access to insurance. Myerson holds a doctorate in public policy from the University of Chicago, a master in public health from the University of Washington, and a bachelor degree from Harvard. Prior to coming to Wisconsin, she was an Assistant Professor at the University of Southern California. Myerson’s policy research has been honored with the ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research, funded by a Fulbright scholarship and the Agency for Healthcare Research and Quality, and cited by the New York Times, Washington Post, NBC Nightly News, and the Centers for Medicare and Medicaid Services.
CDE Research Area Affiliations:
Health & the Life Course
Selected Publications:
Qato, Dima M., John A. Romley, Rebecca Myerson, Dana Goldman, and A. Mark Fendrick. “Shingles Vaccination in Medicare Part D After Inflation Reduction Act Elimination of Cost Sharing.” JAMA (2024).
Dague, Laura, and Rebecca Myerson. “Loss of Medicaid Coverage During the Renewal Process.” In JAMA Health Forum, vol. 5, no. 5, pp. e240839-e240839. American Medical Association, 2024.
Myerson, Rebecca, Dima M. Qato, Dana P. Goldman, and John A. Romley. “Insulin Fills by Medicare Enrollees and Out-of-Pocket Caps Under the Inflation Reduction Act.” JAMA 330, no. 7 (2023): 660-662.
Myerson, Rebecca, and Laura Dague. “Identifying Scalable Strategies To Maintain Coverage As Medicaid Continuous Enrollment Ends.” Health Affairs Forefront (2023).